# Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)

> **NCT01425190** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 16 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Boceprevir

## Key facts

- **NCT ID:** NCT01425190
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01-04
- **Primary completion:** 2013-03-20
- **Final completion:** 2013-03-20
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** The US FDA and the EU CHMP provided guidance indicating preference for intereferon-free regimens in pediatric studies of HCV infection.
- **Last updated:** 2018-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01425190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01425190, "Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01425190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*